Dementia and comorbidities: An overview of diagnosis and management

Journal of Pharmacy Practice

Volumn 20, Issue 4, 2007, Pages 296-317

  Swanson, Keith A ^a   Carnahan, Ryan M ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF PHARMACY   (United States)

Author keywords

Cognitive enhancers; Comorbidities; Delirium; Dementia

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMIODARONE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUSPIRONE; CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CIMETIDINE; CORTICOSTEROID; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; DIGOXIN; DONEPEZIL; GALANTAMINE; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; HUPERZINE A; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KAVA; KETOCONAZOLE; LORAZEPAM; MEMANTINE; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PHYSOSTIGMINE; RIVASTIGMINE; SELEGILINE; TACRINE; UNINDEXED DRUG;

ABDOMINAL PAIN; ALZHEIMER DISEASE; ANOREXIA; ANXIETY DISORDER; BRADYCARDIA; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DELIRIUM; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIARRHEA; DIFFUSE LEWY BODY DISEASE; DISEASE CLASSIFICATION; DISEASE COURSE; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DYSPEPSIA; FRONTOTEMPORAL DEMENTIA; GASTROINTESTINAL SYMPTOM; GENETICS; HEADACHE; HEART BLOCK; HUMAN; HYPERTENSION; IMAGING; LABORATORY; LEWY BODY DEMENTIA; MULTIINFARCT DEMENTIA; NAUSEA; NAUSEA AND VOMITING; PATHOGENESIS; PRACTICE GUIDELINE; PROGNOSIS; PSEUDODEMENTIA; PSYCHIATRY; REVIEW; RISK ASSESSMENT; SEIZURE; SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

EID: 36248932049     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190007308594     Document Type: Review

References (157)

1. Desai AK, Grossberg GT Diagnosis and treatment of Alzheimer's disease. Neurologic disorders update: current thinking and practices. Neurology. 2005 ; 64 (suppl 3). S34 - S39.
2. Sadik K., Wilcock G. The increasing burden of Alzheimer disease. Alzheimer Dis Assoc Disord. 2003 ; 17 (suppl 3). S75 - S79.
3. Herbert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA Alzheimer disease in the US population: prevalence estimates using the 2000 Census. Arch Neurol. 2003 ; 60: 1119-1122.
4. Prigerson HG Costs to society of family caregiving for patients with end-stage Alzheimer's disease. N Engl J Med. 2003 ; 349: 1891-1892.
5. Callahan CM, Hendrie HC, Tierney WM Documentation and evaluation of cognitive impairment in elderly primary care patients. Ann Intern Med. 1995 ; 122: 422-429.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4 th Ed. (DSM-IV-TR). Washington, DC: American Psychiatric Association ; 2000: 143.
7. Gleason OC Delirium. Am Fam Physician. 2003 ; 67: 1027-1034.
8. Morris JC Dementia Update. 2005. Alzheimer Dis Assoc Disord. 2005 ; 19: 100-117.
9. Folstein M., Folstein S., McHugh P. Mini-Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psych Res. 1975 ; 12: 189-198.
10. Guedj E., Barbeau EJ, Didic M., et al. Identification of subgroups in amnestic mild cognitive impairment. Neurology. 2006 ; 67: 356-358.
11. Pfiffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982 ; 37: 323-329.
12. American Geriatrics Society Clinical Practice Committee. Guidelines abstracted from the American Academy of Neurology's Dementia Guidelines for Early Detection, Diagnosis, and Management of Dementia. J Am Geriatr Soc. 2003 ; 55: 869-873.
13. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 ; 56: 1143-1153.
14. Berg L., McKeel DW Jr, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol. 1998 ; 55: 326-335.
15. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan EM Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984 ; 34: 939-944.
16. Pitner JK, Bachman DL A synopsis of the Practice Parameters on Dementia from the American Academy of Neurology on the Diagnosis of Dementia. Consult Pharm. 2004 ; 19: 52-63.
17. Jorm AF The value of informant reports for assessment and prediction of dementia [editoral]. J Am Geriatr Soc. 2003 ; 51: 881-882.
18. Silverman DH, Small GW, Chang CY, et al. Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA. 2001 ; 286: 2120-2127.
19. Martin CM The "reversible" dementia of idiopathic normal pressure hydrocephalus. Consult Pharm. 2006 ; 21: 888-903.
20. Csernansky JG, Wang L., Miller JP, et al. Neuroanatomical predictors of response to donepezil therapy in patients with dementia. Arch Neurology. 2005 ; 62: 1718-1722.
21. Zanni GR, Wick JY Differentiating dementias in long-term care patients. Consult Pharm. 2007 ; 22: 14-28.
22. Zekry D., Hauw JJ, Gold G. Mixed dementia; epidemiology, diagnosis, and treatment. J Am Geriatr Soc. 2002 ; 50: 1431-1438.
23. Peterson RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999 ; 56: 303-308.
24. Gauthier S., Reisberg B., Zaudig M., et al. Mild cognitive impairment. Lancet. 2006 ; 367: 1262-1270.
25. Tschanz JT, Welsh-Bohmer KA, Lyketsos CG, et al. Conversion to dementia from mild cognitive disorder. Neurology. 2006 ; 67 ; 229-234.
26. Visser PJ, Kester A., Jolles J., Verhey F. Ten-year risk of dementia in subjects with mild cognitive impairment. Neurology. 2006 ; 67: 1201-1207.
27. Boyle PA, Wilson RS, Aggarwal NT, Tang Y., Benett DA Risk of Alzheimer disease and rate of cognitive decline. Neurology. 2006 ; 67 ; 441-445.
28. Fischer P., Jungwirth S., Zehetmayer S., et al. Conversion from subtypes of mild cognitive impairment to Alzheimer dementia. Neurology. 2007 ; 68: 288-291.
29. Kryscio RJ, Schmitt FA, Salazar JC, Mendiondo MS, Markesbery RW Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology. 2006 ; 66: 828-832.
30. Hunderfund AL, Roberts RO, Slusser TC, et al. Mortality in amnestic mild cognitive impairment. Neurology. 2006 ; 67 ; 1764-1768.
31. Larson EB, Shadlen MF, Wang L., et al. Survival after initial diagnosis of Alzheimer disease. Ann Intern Med. 2004 ; 140: 105-109.
32. Farlow MR Use of antidementia agents in vascular dementia: beyond Alzheimer disease. Mayo Clin Proc. 2006 ; 81: 1350-1358.
33. Tiraboschi P., Hansen LA, Alford M., et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psych. 2002 ; 59: 946-951.
34. Milisen K., Graes T., Fick DM, et al. Cognitive assessment and differentiating the 3 Ds (dementia, depression, delirium). Nurs Clin North Am. 2006 ; 41: 1-22.
35. Kasahara H., Tsumura M., Ochiai Y., et al. Consideration of the relationship between depression and dementia. Psychogeriatrics. 2006 ; 6: 128-133.
36. Langa KM, Foster NL, Larson EB Mixed dementia; emerging concepts and therapeutic implications. JAMA. 2004 ; 292: 2901-2908.
37. Aisen PS, Schafer KA, Grundman, et al. Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003 ; 289: 2819-2826.
38. Murray MD, Lane KA, Gao S., et al. Preservation of cognitive function with antihypertensive medications. Arch Intern Med. 2002 ; 162: 2090-2096.
39. Kalmjn S., Van Boxtel MPJ, Ocke M., et al. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology. 2004 ; 62: 275-280.
40. Stampfer MJ, Kang JH, Chen J., et al. Effects of moderate alcohol consumption on cognitive function in women. N Engl J Med. 2005 ; 352: 245-253.
41. Engelhart MJ, Geerlings MI, Ruitenberg A., et al. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA. 2002 ; 287: 3223-3229.
42. Miller ER III, Pastor-Barriuso R., Dalal D., et al. Meta-analysis: high dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005 ; 142: 37-46.
43. Smyth KA, Fritsch T., Cook TB, McClendon MJ, Santillan CE, Friedland RP Worker functions and traits associated with occupations and the development of AD. Neurology. 2004 ; 63: 498-503.
44. Wilson RS, Bennett DA, Bienias JL, et al. Cognitive activity and incident Alzheimer's disease in a population-based sample of older persons. Neurology. 2002 ; 59: 1910 -1914.
45. Levy ML Cholinergic therapy for Alzheimer's disease. Ann Long-Term Care. 1998 ; 6: 1524-1529.
46. Scarpini E., Scheltens P., Feldman H. Treatment of Alzheimer's disease: current status and new perspectives. Lancet Neurol. 2003 ; 2: 539-547.
47. American Association for Geriatric Psychiatry. AAGP Position Statement: Principles of Care for Patients with Dementia Resulting from Alzheimer Disease. (2005) http://www.aagponline.org/prof/position_caredmnalz.asp. Accessed May 1, 2007.
48. Cohen-Mansfield J., Werner P. Management of verbally disruptive behaviors in nursing home residents. J Gerontol A Biol Sci Med Sci. 1997 ; 52: M369 - M377.
49. Cohen-Mansfield J. Nonpharmacologic interventions for inappropriate behaviors in dementia: a review, summary, and critique. Am J Geriatr Psychiatry. 2001 ; 9: 361-381.
50. Brodaty H., Green A., Koschera A. Meta-analysis of psychosocial interventions for caregivers of people with dementia. J Am Geriatr Soc. 2003 ; 51: 657-664.
51. Woods RT, Moniz-Cook E., Iliffe S., et al. Dementia: issues in early recognition and intervention in primary care. J Royal Soc Med. 2003 ; 96: 320-324.
52. Delagarza V. Pharmacologic treatment of Alzheimer's disease: an update. Am Fam Physician. 2003 ; 68: 1365-1372.
53. Winblad B., Jelic V. Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Dis Assoc Disord. 2004 ; 18 (suppl 1). S2 - S8.
54. Linnebur SA, Ruscin JM Cholinesterase inhibitor use in geriatric outpatients with dementia. Am J Health Syst Pharm. 2005 ; 62: 923-926.
55. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer's disease and related disorders: consensus statement of the American Association of Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA. 1997 ; 278: 1363-1371.
56. Mayeux R. Sano M. Treatment of Alzheimer's disease. N Eng J Med. 1999 ; 341: 1670-1679.
57. Francis PT, Palmer AM, Snape M., Wilcock GK The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurology Neurosurg Psychiatry. 1999 ; 66: 137-147.
58. Cummings JL Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry. 2000 ; 157: 4-15.
59. Pietrzik C., Behl C. Concepts for the treatment of Alzheimer's disease: molecular mechanisms and clinical application. Int J Exp Path. 2005 ; 86 ; 173-185.
60. Doody RS, Stevens JC, Beck C., et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001 ; 56: 1154-1166.
61. de la Torre J., Aliev G., Perry G. Drug Therapy in Alzheimer's Disease. N Engl J Med. 2004 ; 351: 1911-1913.
62. Doody RS Refining treatment guidelines in Alzheimer's disease. Geriatrics. 2005 :Suppl: 14-20.
63. Demaerschalk BM, Wingerchuck DM Treatment of vascular dementia and vascular cognitive impairment. Neurologist. 2007 ; 13: 37-41.
64. Wolfson C., Wolfson DB, Asgharian M., et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001 ; 344: 1111-1116.
65. Gracon SI, Knapp MJ, Berghoff WG, et al. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis Assoc Disord. 1998 ; 12: 93-101.
66. Rogers S., Farlow M., Doody R., Mohs R., Friedhoff L. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998 ; 50: 136-145.
67. Burns A., Rossor M., Hecker J., et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord. 1999 ; 10: 237-244.
68. Boada-Rovira M., Brodaty H., Cras P., et al. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study. Drugs Aging. 2004 ; 21: 43-53.
69. Exelon [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation ; 2006.
70. Corey-Bloom J. Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int J Clin Pract. 2003 ; 57: 219-223.
71. Collins B., Constant J., Kaba S., Barclay CL, Mohr E. Dementia with Lewy bodies: implications for clinical trials. Clin Neuro-pharmacol. 2004 ; 27: 281-292.
72. Farlow MR, Small GW, Quarg P., Krause A. Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis. Dement Geriatr Cogn Disord. 2005 ; 20: 192-197.
73. Gauthier S., Emre M., Farlow MR, Bullock R., Grossberg GT, Potkin SG Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin. 2003 ; 19: 707-714.
74. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S., Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004 ; 291: 317-324.
75. Farlow MR Utilizing combination therapy in the treatment of Alzheimer's disease. Exp Rev Neurother. 2004 ; 4: 799-808.
76. Bullock R., Dengiz A. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Int J Clin Pract. 2005 ; 59: 817-822.
77. Farlow MR, Lilly ML ENA713 B352 Study Group. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatr. 2005 ; 5: 3.
78. Trinh N., Hoblyn J., Mohanty S., Yaffe K. The efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease. JAMA. 2003 ; 289: 210-216.
79. Cummings JL, Koumaras B., Chen M., Mirski D. Rivastigmine Nursing Home Study Team. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study. Am J Ger Pharmacother. 2005 ; 3: 137-148.
80. Cummings JL, Schneider L., Tariot PN, Kershaw PR, Yuan W. Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease. Am J Psychiatry. 2004 ; 161: 532-538.
81. Reisberg B., Doody R., Stoffler A., Schmitt F., Ferris S., Mobius HJ Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 ; 348: 1333-1341.
82. Farlow MR NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease. Geriatrics. 2004 ; 59: 22-27.
83. Sano M., Ernesto C., Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 1997 ; 336: 1216-1222.
84. Birks J., Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev. 2003: CD000442.
85. Van Dongen M., van Rossum E., Kessels A., et al. Ginkgo for elderly people with dementia and age-associated memory impairment: a randomized clinical trial. J Clin Epidemiol. 2003 ; 56: 367-376.
86. Oken BS, Storzbach DM, Kaye JA The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol. 1998 ; 55: 1409-1415.
87. Solomon PR, Adams F., Silver A., Zimmer J., DeVeaux R. Ginkgo for memory enhancement: a randomized controlled trial. JAMA. 2002 ; 288: 835-840.
88. Ott BR, Owens NJ Complementary and alternative medicines for Alzheimer's disease. J Geriatr Psychiatry Neurol. 1998 ; 11: 163-173.
89. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL A potential role of the curry spice curcumin in Alzheimer's disease. Curr Alzheimer Res. 2005 ; 2: 131-136.
90. Gold JL, Laxer DA, Dergal JM, Lanctot KL, Rochon PA Herbal-drug therapy interactions: a focus on dementia. Curr Opin Clin Nutr Metab Care. 2001 ; 4: 29-34.
91. Petersen RC, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005 ; 352: 2379-2388.
92. Lahiri DK, Farlow MR, Sambamurti K., Greig NH, Giacobini E., Schneider LS A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Curr Drug Targets. 2003 ; 4: 97-112.
93. Caeiro L Ferro JM, Claro MI, Coelho J., Albuquerque R., Figueira ML Delirium in acute stroke: a preliminary study of the role of anticholinergic medications. Eur J Neurol. 2004 ; 11: 699-704.
94. Agostini Leo-Summers LS, Inouye SK. Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients. Arch Intern Med. 2001 ; 161: 2091-2097.
95. Nelson JE Tandon N., Mercado AF, Camhi SL, Ely EW, Morrison RS Brain dysfunction: another burden for the chronically critically ill. Arch Intern Med. 2006 ; 166: 1993-1999.
96. Furlaneto ME, Garcez-Leme LE Delirium in elderly individuals with hip fracture: causes, incidence, prevalence, and risk factors. Clinics. 2006: 61: 35-40.
97. Milisen K., Foreman MD, Wouters B., et al. Documentation of delirium in elderly patients with hip fracture. J Gerontol Nurs. 2002 ; 28: 23-29.
98. Hustey FM, Meldon SW The prevalence and documentation of impaired mental status in elderly emergency department patients. Ann Emerg Med. 2002 ; 39: 248-253.
99. Marcantonio ER, Juarez G., Goldman L., et al. The relationship of postoperative delirium with psychoactive medications. JAMA. 1994 ; 272: 1518-1522.
100. Marcantonio ER, Flacker JM, Michaels M., Resnick NM Delirium is independently associated with poor functional recovery after hip fracture. J Am Geriatr Soc. 2000 ; 48: 618-624.
101. Gustafson Y., Berggren D., Brannstrom B., et al. Acute confusional states in elderly patients treated for femoral neck fracture. J Am Geriatr Soc. 1988 ; 36: 525-530.
102. Kiely DK, Jones RN, Bergmann MA, Murphy KM, Orav EJ, Marcantonio ER Association between delirium resolution and functional recovery among newly admitted postacute facility patients. J Gerontol A Biol Sci Med Sci. 2006 ; 61: 204-208.
103. Carnahan RM, Lund BC, Perry PJ, Pollock BG A critical appraisal of the utility of the serum anticholinergic assay in research and clinical practice. Psychopharmacol Bull. 2002 ; 36: 24-39.
104. Fick DM, Agostini JV, Inouye SK Delirium superimposed on dementia: a systematic review. J Am Geriatr Soc. 2002 ; 50: 1723-1732.
105. Inouye SK, Van Dyck CH, Alessi CA, et al. Clarifying confusion: the confusion assessment method. A new method for detecting delirium. Ann Intern Med. 1990 ; 113: 941-948.
106. Jacobi J., Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002 ; 30: 119-141.
107. Ely EW, Margolin R., Francis J., et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001 ; 29: 1370-1379.
108. Laible B. Delirium in the intensive care unit. J Pharm Pract. In press.
109. Landi F., Onder G., Cessari M., Barillaro C., Russo A., Bernabei R. Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J Gerontol A Biol Sci Med Sci. 2005 ; 60: 622-26.
110. Malone M., Carnahan RM, Kutscher EC Antipsychotic use in the elderly. J Pharm Pract. 2007 ; 20: 318 - 326.
111. Overshot R., Burns A. Cholinesterase inhibitors: in search of cholinergic deficits. Adv Psychiatr Treat. 2005 ; 11: 321-324.
112. Heiser JF, Gillin JC The reversal of anticholinergic drug-induced delirium and coma with physostigmine. Am J Psychiatry. 1971 ; 127: 1050-1054.
113. Gowdy JM Stramonium intoxication: review of symptomatology in 212 cases. JAMA. 1972 ; 221: 585-587.
114. Pentel P., Peterson CD Asystole complication physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980 ; 9: 588.
115. Breitbart W., Marotta R., Platt MM, et al. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry. 1996 ; 153: 231-237.
116. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean R., Beers MH Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a U.S. panel of experts. Arch Intern Med. 2003 ; 163: 2716-2724.
117. Carnahan RM, Lund BC, Perry PJ, Chrischilles EA The concurrent use of anticholinergic drugs with cholinesterase inhibitors: rare event or common practice? J Am Geriatr Soc. 2004 ; 52: 2082-2087.
118. Gill SS, Mamdani M., Naglie G., et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005 ; 165: 808-813.
119. Roe CM, Anderson MJ, Spivack B. Use of anticholinergic medications by older adults with dementia. Am Geriatr Soc. 2002 ; 50: 836-842.
120. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR The Anticholinergic Drug Scale as a measure of anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006 ; 46: 1481-1486.
121. Martin BK, Frangakis CE, Rosenberg PB, et al. Design of depression in Alzheimer's Disease Study-2. Am J Geriatr Psychiatry. 2006 ; 14: 920-930.
122. Olin JT, Katz IR, Meyers BS, Schneider LS, Lebowitz BD Provisional diagnostic criteria for depression of Alzheimer disease: rationale and background. Am J Geriatr Psychiatry. 2002 ; 10: 129-141.
123. Zubenko GS, Zubenko WN, McPherson S., et al. A collaborative study of the emergence and clinical features of the major depressive syndrome of Alzheimer's disease. Am J Psychiatry. 2003 ; 160: 857-866.
124. Li Y., Meyer JS, Thornby J. Longitudinal follow-up of depressive symptoms in normal versus cognitively impaired elderly. Int J Geriatr Psychiatry. 2001 ; 16: 718-727.
125. Sultzer DL, Levin HS, Mahler ME, High WM, Cummings JL A comparison of psychiatric symptoms in vascular dementia and Alzheimer's disease. Am J Psychiatry. 1993 ; 150: 1806-1812.
126. Lyketsos CG, Steele C., Galik E., et al. Physical aggression in dementia patients and its relationship to depression. Am J Psychiatry. 1999 ; 156: 66-71.
127. Herrmann N. Use of SSRIs in the elderly: obvious benefits but unappreciated risks. Can J Clin Pharmacol. 2000 ; 7: 91-95.
128. Teri L., Logsdon RG, Uomoto J., et al. Behavioral treatment of depression in dementia patients: a controlled clinical trial. J Gerontol B Psychol Sci Soc Sci. 1997 ; 52: 159-166.
129. Meyers BS Depression and dementia: comorbidities identification and treatment. J Geriatr Psychiatry Neurol. 1998 ; 11: 201-205.
130. Lyketsos CG, Lopez O., Jones B., Fitzpatrick AL, Breitner J., DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and cognitive impairment: results from the Cardiovascular Health Study. JAMA. 2002 ; 288: 1475-1483.
131. Luxenburg JS Clinical issues in the behavioural and psychological symptoms of dementia. Int J Geriatr Psychiatry. 2000 ; 15: S5 - S8.
132. Finnema E., Droes RM, Ettema T., et al. The effect of integrated emotion-oriented care versus usual care on elderly persons with dementia in the nursing home and on nursing assistants: a randomized clinical trial. Int J Geriatr Psychiatry. 2005 ; 20: 330-343.
133. Tune LE, Bylsma FW Benzodiazepine-induced and anticholinergic-induced delirium in the elderly. Int Psychogeriatr. 1991 ; 3: 397-408.
134. Lyketsos CG, Corazzini K., Steele C. Mania in Alzheimer's disease. J Neuropsychiatry Clin Neurosci. 1995 ; 7: 350-352.
135. Wilson RS, Gilley DW, Bennett DA, Beckett LA, Evans DA Hallucinations, delusions, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2000 ; 69: 172-177.
136. Gormley N., Rizwan MR, Lovestone S. Clinical predictors of aggressive behaviour in Alzheimer's disease. Int J Geriatr Psychiatry. 1998 ; 13: 109-115.
137. Chapman FM, Dickinson J., McKeith I., Ballard C. Association of visual hallucinations, visual acuity, and specific eye pathologies in Alzheimer's disease: treatment implications. Am J Psychiatry. 1999 ; 156: 1983-1985.
138. Aarsland D., Cummings JL, Yenner G., Miller B. Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer's disease. Am J Psychiatry. 1996 ; 153: 243-247.
139. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotics in patients with Alzheimer's disease. N Engl J Med. 2006 ; 355: 1525-1538.
140. Schneider LS, Dagerman KS, Insel P. Risk of death associated with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005 ; 294: 1934-1943.
141. Schneeweiss S., Setoguchi S., Brookhart A., Dormuth C., Wang PS Risk of death associated with conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007 ; 176: 627-632.
142. Lee PE, Sykora K., Gill SS, et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc. 2005 ; 53: 1374-1379.
143. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia. JAMA. 2005 ; 293: 596-608.
144. Nagaratnam N., Lewis-Jones M., Scott D., Palazzi L. Behavioral and psychiatric manifestations in dementia patients in a community: caregiver burden and outcome. Alzheimer Dis Assoc Disord. 1998 ; 330-334.
145. Cohen-Mansfield J., Mintzer JE Time for change: the role of nonpharmacological interventions in treating behavior problems in nursing home residents with dementia. Alzheimer Dis Assoc Disord. 2005 ; 19: 37-40.
146. Cohen-Mansfield J., Billig N. Agitated behaviors in the elderly. I. A conceptual review. J Am Geriatr Soc. 1986 ; 34: 711-721.
147. Cohen-Mansfield J., Lipson S., Werner P., Billig N., Taylor L., Woosley R. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med. 1999 ; 159: 1733-1740.
148. Thapa PB, Meador KG, Gideon P., Fought RL, Ray WA Effects of antipsychotic withdrawal in elderly nursing home residents. J Am Geriatr Soc. 1994 ; 42: 280-286.
149. Cohen-Mansfield J., Garfinkel D., Lipson S. Melatonin for treatment of sundowning in elderly persons - a preliminary study. Arch Gerontol Geriatr. 2000 ; 31: 65-76.
150. Asayama K., Yamadera H., Ito T., Suzuki H., Kudo Y., Endo S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J Nippon Med Sch. 2003 ; 70: 334-341.
151. Walther S., Mahlberg R., Eichman U., Kunz D. Delta-9-tetrahydocannabinol for nighttime agitation in severe dementia. Psychopharmacology. 2006 ; 185: 524-528.
152. Skjerve A., Bjorvatn B., Holsten F. Light therapy for behavioural and psychological symptoms of dementia. Int J Geriatr Psychiatry. 2004 ; 19: 516-522.
153. Neef D., Walling AD Dementia with Lewy bodies: an emerging disease. Am Fam Physician. 2006 ; 73: 1223-1229.
154. Miyasaki JM, Shannon K., Voon V.,, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 ; 66: 996-1002.
155. Allain H., Bentué-Ferrer D., Tribut O., Mérienne M., Belliard S. Drug therapy of frontotemporal dementia. Hum Psych-pharmacol Clin Exp. 2003 ; 18: 221-225.
156. Moretti R., Torre P., Antonello RM, et al. Rivastigmine in frontotemporal dementia: an open-label study. Drugs Aging. 2004 ; 21: 931-937.
157. Pijnenburg YA, Sampson EL, Harvey RJ, Fox NC, Rossor MN Vulnerability to neuroleptic side effects in frontotemporal lobar degeneration. Int J Geriatr Psychiatry. 2003 ; 18: 67-62.